Novartis shares jump after positive data in experimental heart treatment
Novartis released results for two of three watched trials in the second half of the year. U.S.-listed shares soared 6% Tuesday to $161.25 on positive study data for an experimental treatment for…
By Catherine DunnIn a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.Novartis saw U.S.-listed shares soar 6% Tuesday, to $161.25, on positive study data for an experimental treatment for…